Sudan    B-Naphthalene114958564
I    I-Naphthalene114958564
(    O
also    O
commonly    O
known    O
as    O
CI    B-Naphthalene114958564
Solvent    I-Naphthalene114958564
Yellow    I-Naphthalene114958564
14    I-Naphthalene114958564
and    O
Solvent    B-Naphthalene114958564
Orange    I-Naphthalene114958564
R    I-Naphthalene114958564
)    O
,    O
is    O
an    O
organic    O
compound    O
,    O
typically    O
classified    O
as    O
an    O
azo    O
dye    O
.    O

Solvent    B-Naphthalene114958564
Yellow    I-Naphthalene114958564
14    I-Naphthalene114958564
(    O
C.I.    O
12055    O
)    O

AC-262536    B-Naphthalene114958564
is    O
a    O
drug    O
developed    O
by    O
Acadia    O
Pharmaceuticals    O
which    O
acts    O
as    O
a    O
selective    O
androgen    O
receptor    O
modulator    O
.    O

Rifaximin    B-Naphthalene114958564
,    O
sold    O
under    O
the    O
trade    O
name    O
Xifaxan    B-Naphthalene114958564
among    O
others    O
,    O
is    O
an    O
antibiotic    O
used    O
to    O
treat    O
traveler    O
's    O
diarrhea    O
,    O
irritable    O
bowel    O
syndrome    O
,    O
and    O
hepatic    O
encephalopathy    O
.    O

Rifaximin    B-Naphthalene114958564
may    O
also    O
be    O
useful    O
.    O

Rifaximin    B-Naphthalene114958564
is    O
approved    O
in    O
the    O
U.S.    O
for    O
treatment    O
of    O
TD    O
caused    O
by    O
ETEC    O
.    O

It    O
has    O
been    O
show    O
to    O
efficiently    O
decolorize    O
several    O
structurally    O
different    O
different    O
synthetic    O
dyes    O
:    O
amaranth    B-Naphthalene114958564
,    O
Remazol    O
Brilliant    O
Blue    O
R    O
,    O
Phthalocyanine    O
Blue    O
BN    O
,    O
and    O
Poly    O
R-478    O
.    O
"    O
Ischnoderma    O
benzoinum    O
"    O
has    O
antiviral    O
activity    O
against    O
type    O
A    O
influenza    O
virus    O
of    O
birds    O
and    O
humans    O
.    O

Amaranth    B-Naphthalene114958564
(dye)    I-Naphthalene114958564
,    O
a    O
dark    O
red    O
to    O
purple    O
dye    O
once    O
used    O
for    O
coloring    O
food    O
(    O
FD&C    O
Red    O
No    O
.    O
2    O
)    O
but    O
now    O
banned    O
by    O
the    O
United    O
States    O
Food    O
and    O
Drug    O
Administration    O

Also    O
a    O
synthetic    O
dye    O
was    O
named    O
"    O
amaranth    B-Naphthalene114958564
"    O
for    O
its    O
similarity    O
in    O
color    O
to    O
the    O
natural    O
amaranth    O
pigments    O
known    O
as    O
betalains    O
.    O

bunaftine    B-Naphthalene114958564
(    O
INN    O
)    O

Although    O
mevastatin    B-Naphthalene114958564
never    O
became    O
an    O
approved    O
drug    O
,    O
the    O
mevastatin    O
derivative    O
pravastatin    O
did    O
.    O

mevastatin    B-Naphthalene114958564
(    O
INN    O
)    O

Bedaquiline    B-Naphthalene114958564
(    O
TMC207/R207910    O
,    O
tradename    O
Sirturo    O
)    O
,    O
an    O
diarylquinoline    O
anti    O
-    O
tuberculosis    O
drug    O

Bedaquiline    B-Naphthalene114958564

With    O
a    O
Schrock    O
catalyst    O
modified    O
with    O
a    O
BINOL    B-Naphthalene114958564
ligand    O
in    O
a    O
norbornadiene    O
ROMP    O
leading    O
to    O
highly    O
stereoregular    O
cis    O
,    O
isotactic    O
polymer    O
.    O

Indole    O
reacts    O
with    O
an    O
enamide    O
catalyzed    O
by    O
a    O
chiral    O
BINOL    B-Naphthalene114958564
derived    O
phosphoric    O
acid    O
:    O

In    O
2012    O
,    O
a    O
BINOL    B-Naphthalene114958564
-    O
derived    O
catalyst    O
was    O
employed    O
to    O
generate    O
chiral    O
cyanide    O
anion    O
.    O

Other    O
phosphine    O
asymmetric    O
ligands    O
were    O
known    O
at    O
the    O
time    O
(    O
DIPAMP    O
,    O
BINOL    B-Naphthalene114958564
,    O
CHIRAPHOS    O
)    O
but    O
the    O
new    O
ligand    O
was    O
found    O
to    O
be    O
more    O
effective    O
.    O

Antifungal    O
treatments    O
include    O
topical    O
agents    O
such    O
as    O
miconazole    O
,    O
terbinafine    O
,    O
clotrimazole    O
,    O
ketoconazole    O
,    O
or    O
tolnaftate    B-Naphthalene114958564
applied    O
twice    O
daily    O
until    O
symptoms    O
resolve    O
—    O
usually    O
within    O
one    O
or    O
two    O
weeks    O
.    O

Topical    O
antifungals    O
,    O
such    O
as    O
:    O
Terbinafine    O
,    O
Tolnaftate    B-Naphthalene114958564
,    O
and    O
orally    O
administered    O
Griseofulvin    O
have    O
been    O
used    O
successfully    O
to    O
treat    O
"    O
M.    O
gallinae    O
"    O
infections    O
in    O
humans    O
and    O
animals    O
.    O

Madden    O
has    O
appeared    O
in    O
a    O
variety    O
of    O
radio    O
and    O
television    O
commercials    O
including    O
Ace    O
Hardware    O
,    O
Outback    O
Steakhouse    O
(    O
the    O
corporate    O
sponsor    O
of    O
the    O
"    O
Maddencruiser    O
"—    O
see    O
above    O
under    O
"    O
Fear    O
of    O
flying    O
"    O
)    O
,    O
Verizon    O
Wireless    O
,    O
Rent    O
-    O
A    O
-    O
Center    O
,    O
Miller    O
Lite    O
,    O
Toyota    O
,    O
Sirius    O
Satellite    O
Radio    O
and    O
Tinactin    B-Naphthalene114958564
.    O

pamoic    B-Naphthalene114958564
acid    I-Naphthalene114958564

CSP-2503    B-Naphthalene114958564
—    O
anxiolytic    O

Streptomyces    O
phaeochromogenes    O
"    O
produces    O
tyrosinate    O
,    O
bromoperoxidase    O
,    O
ditryptophenalin    O
,    O
phaeochromycin    B-Naphthalene114958564
A    I-Naphthalene114958564
,    O
phaeochromycin    O
B    O
,    O
phaeochromycin    O
C    O
,    O
phaeochromycin    O
D    O
and    O
phaeochromycin    O
E.    O

As    O
with    O
dynemicin    O
A    O
,    O
neocarzinostatin    B-Naphthalene114958564
also    O
interacts    O
with    O
DNA    O
.    O

Some    O
examples    O
:    O
Sudan    O
IV    O
,    O
Oil    B-Naphthalene114958564
Red    I-Naphthalene114958564
O    I-Naphthalene114958564
,    O
and    O
Sudan    B-Naphthalene114958564
Black    I-Naphthalene114958564
B    I-Naphthalene114958564

Olympiadane    B-Naphthalene114958564

Angiotensin    O
converting    O
enzyme    O
inhibitors    O
,    O
beta    O
-    O
blockers    O
,    O
antiplatelet    O
agents    O
(    O
aspirin    O
and    O
clopidogrel    O
)    O
,    O
naftidrofuryl    B-Naphthalene114958564
,    O
pentoxifylline    O
,    O
and    O
cilostazol    O
(    O
selective    O
PDE3    O
inhibitor    O
)    O
are    O
used    O
for    O
the    O
treatment    O
of    O
intermittent    O
claudication    O
.    O

α-Vetivone    B-Naphthalene114958564
is    O
an    O
organic    O
compound    O
that    O
is    O
classified    O
as    O
a    O
sesquiterpene    O
(    O
derived    O
from    O
three    O
isoprene    O
units    O
)    O
.    O

Differentiated    O
Adipocyte    O
stained    O
with    O
Oil    B-Naphthalene114958564
Red    I-Naphthalene114958564
O    I-Naphthalene114958564

Solvent    B-Naphthalene114958564
Red    I-Naphthalene114958564
27    I-Naphthalene114958564
(    O
C.I.    O
26125    O
)    O

An    O
important    O
subclass    O
of    O
these    O
compounds    O
are    O
the    O
naphthalen-1,8-diyl    B-Naphthalene114958564
1,3,2,4-dithiadiphosphetane    I-Naphthalene114958564
2,4-disulfide    I-Naphthalene114958564
;    O
these    O
are    O
intellectually    O
interesting    O
because    O
the    O
two    O
dithiophosphine    O
ylides    O
are    O
fixed    O
together    O
in    O
space    O
by    O
the    O
rigid    O
naphthalene    O
unit    O
.    O

SRT2183    B-Naphthalene114958564

CB-13    B-Naphthalene114958564
(    O
CRA13    B-Naphthalene114958564
,    O
SAB-378    B-Naphthalene114958564
)    O
is    O
a    O
cannabinoid    O
drug    O
,    O
which    O
acts    O
as    O
a    O
potent    O
agonist    O
at    O
both    O
the    O
CB1    O
and    O
CB2    O
receptors    O
,    O
but    O
has    O
poor    O
blood–    O

:    O
Acid    O
fuchsin    O
,    O
xylidine    O
ponceau    O
,    O
chromotrope    O
2R    O
,    O
Biebrich    B-Naphthalene114958564
scarlet    I-Naphthalene114958564
,    O
ponceau    O
6R    O
,    O
phloxine    O

Agomelatine    B-Naphthalene114958564
(    O
antidepressant    O
)    O

Antidepressant    O
(    O
antagonists    O
;    O
e.g.    O
agomelatine    B-Naphthalene114958564
,    O
fluoxetine    O
,    O
mirtazapine    O
)    O

All    O
currently    O
marketed    O
antidepressants    O
have    O
the    O
monoamine    O
hypothesis    O
as    O
their    O
theoretical    O
basis    O
,    O
with    O
the    O
possible    O
exception    O
of    O
agomelatine    B-Naphthalene114958564
which    O
acts    O
on    O
a    O
dual    O
melatonergic    O
-    O
serotonergic    O
pathway    O
.    O

Because    O
of    O
its    O
affinity    O
for    O
serotonin    O
receptors    O
,    O
it    O
has    O
potential    O
to    O
serve    O
as    O
a    O
possible    O
antidepressant    O
drug    O
,    O
similar    O
to    O
agomelatine    B-Naphthalene114958564
.    O

JWH-122    B-Naphthalene114958564

JWH-122    B-Naphthalene114958564

Oxazine    O
derivatives    O
:    O
Nile    B-Naphthalene114958564
red    I-Naphthalene114958564
,    O
Nile    B-Naphthalene114958564
blue    I-Naphthalene114958564
,    O
cresyl    O
violet    O
,    O
oxazine    O
170    O
,    O
etc    O
.    O

Other    O
methods    O
of    O
staining    O
are    O
available    O
;    O
examples    O
are    O
SYBR    O
Green    O
,    O
GelRed    O
,    O
methylene    O
blue    O
,    O
brilliant    O
cresyl    O
blue    O
,    O
Nile    B-Naphthalene114958564
blue    I-Naphthalene114958564
sulphate    O
,    O
and    O
crystal    O
violet    O
.    O

The    O
use    O
of    O
axially    O
chiral    O
biaryl    O
compounds    O
such    O
as    O
BINAP    B-Naphthalene114958564
,    O
QUINAP    O
and    O
BINOL    B-Naphthalene114958564
,    O
have    O
been    O
found    O
to    O
be    O
useful    O
in    O
the    O
area    O
of    O
asymmetric    O
catalysis    O
as    O
chiral    O
ligands    O
.    O

An    O
example    O
of    O
an    O
asymmetric    O
synthesis    O
by    O
conjugate    O
addition    O
is    O
the    O
synthesis    O
of    O
(    O
R)-3-phenyl    O
-    O
cyclohexanone    O
from    O
cyclohexenone    O
,    O
phenylboronic    O
acid    O
,    O
a    O
rhodium    O
acac    O
catalyst    O
and    O
the    O
chiral    O
ligand    O
BINAP    B-Naphthalene114958564
.    O

Of    O
these    O
the    O
BINAP    B-Naphthalene114958564
ligand    O
is    O
perhaps    O
the    O
best    O
-    O
known    O
,    O
as    O
a    O
result    O
of    O
its    O
Nobel    O
Prize    O
-    O
winning    O
application    O
in    O
the    O
Noyori    O
asymmetric    O
hydrogenation    O
.    O

One    O
of    O
these    O
was    O
reported    O
in    O
2003    O
,    O
when    O
a    O
heterogeneous    O
catalyst    O
was    O
reported    O
that    O
included    O
structural    O
zirconium    O
,    O
catalytically    O
active    O
ruthenium    O
,    O
and    O
a    O
BINAP    B-Naphthalene114958564
-    O
derived    O
phosphonate    O
as    O
both    O
chiral    O
ligand    O
and    O
structural    O
linker    O
.    O

Asymmetric    O
hydrosilylation    O
of    O
ketones    O
to    O
chiral    O
secondary    O
alcohols    O
with    O
good    O
yields    O
and    O
excellent    O
enantioselectivities    O
using    O
Cu    O
-    O
Al    O
hydrotalcite    O
and    O
BINAP    B-Naphthalene114958564
has    O
opened    O
up    O
a    O
new    O
perspective    O
.    O

litoxetine    B-Naphthalene114958564
(    O
INN    O
)    O

Brilliant    B-Naphthalene114958564
Black    I-Naphthalene114958564
BN    I-Naphthalene114958564
,    O
Brilliant    B-Naphthalene114958564
Black    I-Naphthalene114958564
PN    I-Naphthalene114958564
,    O
Brilliant    B-Naphthalene114958564
Black    I-Naphthalene114958564
A    I-Naphthalene114958564
,    O
Black    B-Naphthalene114958564
PN    I-Naphthalene114958564
,    O
Food    B-Naphthalene114958564
Black    I-Naphthalene114958564
1    I-Naphthalene114958564
,    O
Naphthol    B-Naphthalene114958564
Black    I-Naphthalene114958564
,    O
C.I.    B-Naphthalene114958564
Food    I-Naphthalene114958564
Black    I-Naphthalene114958564
1    I-Naphthalene114958564
,    O
or    O
C.I.    B-Naphthalene114958564
28440    I-Naphthalene114958564
,    O
is    O
a    O
synthetic    O
black    O
diazo    O
dye    O
.    O

Sensipar/Mimpara    B-Naphthalene114958564
(Cinacalcet)    I-Naphthalene114958564
(    O
for    O
Primary    O
&    O
Secondary    O
hyperparathyroidism    O
,    O
a    O
mineral    O
metabolism    O
complication    O
common    O
in    O
patients    O
with    O
kidney    O
failure    O
)    O

If    O
hypophosphatemia    O
persists    O
despite    O
calcitriol    O
and    O
phosphate    O
supplementation    O
,    O
administration    O
of    O
cinacalcet    B-Naphthalene114958564
has    O
been    O
shown    O
to    O
be    O
useful    O

Sensipar    O
(    O
cinacalcet    B-Naphthalene114958564
)    O

The    O
stability    O
of    O
halocarbons    O
tended    O
to    O
encourage    O
beliefs    O
that    O
they    O
were    O
mostly    O
harmless    O
,    O
although    O
in    O
the    O
mid-1920s    O
physicians    O
reported    O
workers    O
in    O
polychlorinated    B-Naphthalene114958564
naphthalene    I-Naphthalene114958564
manufacturing    O
suffering    O
from    O
chloracne    O
,    O
and    O
by    O
the    O
late    O
1930s    O
it    O
was    O
known    O
that    O
workers    O
exposed    O
to    O
PCN    B-Naphthalene114958564
could    O
die    O
from    O
liver    O
disease    O
and    O
that    O
DDT    O
would    O
kill    O
mosquitos    O
and    O
other    O
insects    O
.    O

A    O
specific    O
class    O
of    O
Cl    O
-    O
PAHs    O
,    O
polychlorinated    B-Naphthalene114958564
naphthalene    I-Naphthalene114958564
(    O
PCNs    O
)    O
,    O
are    O
persistent    O
,    O
bioaccumulative    O
,    O
and    O
toxic    O
contaminants    O
that    O
have    O
been    O
reported    O
to    O
occur    O
in    O
a    O
wide    O
variety    O
of    O
environmental    O
and    O
biological    O
matrixes    O
.    O

Pronethalol    B-Naphthalene114958564

Retene    O
,    O
together    O
with    O
cadalene    B-Naphthalene114958564
,    O
simonellite    O
and    O
ip    O
-    O
iHMN    O
,    O
is    O
a    O
biomarker    O
of    O
higher    O
plants    O
,    O
which    O
makes    O
it    O
useful    O
for    O
paleobotanic    O
analysis    O
of    O
rock    O
sediments    O
.    O

#    O
"    O
Red    B-Naphthalene114958564
#40    I-Naphthalene114958564
"    O
–    O
3:39    O

Artificial    O
colors    O
(    O
Yellow    O
6    O
,    O
Blue    O
1    O
,    O
Yellow    O
5    O
and    O
Red    B-Naphthalene114958564
40    I-Naphthalene114958564
)    O

Glucose    O
Syrup    O
(    O
corn    O
starch    O
,    O
water    O
)    O
,    O
sugar    O
,    O
sweet    O
rice    O
,    O
water    O
,    O
lemon    O
flavor    O
,    O
orange    O
flavor    O
,    O
FD&C    B-Naphthalene114958564
Red    I-Naphthalene114958564
No.    I-Naphthalene114958564
40    I-Naphthalene114958564
(    O
Allura    B-Naphthalene114958564
Red    I-Naphthalene114958564
AC    I-Naphthalene114958564
)    O
.    O

Alternate    O
ingredient    O
list    O
:    O
Millet    O
Jelly    O
(    O
millet    O
starch    O
,    O
water    O
)    O
,    O
sugar    O
,    O
sweet    O
rice    O
,    O
water    O
,    O
lemon    O
flavor    O
,    O
orange    O
flavor    O
,    O
FD&C    O
red    O
no    O
.    O
40    O
(    O
Allura    B-Naphthalene114958564
Red    I-Naphthalene114958564
AC    I-Naphthalene114958564
)    O
.    O

USA    O
import    O
:    O
corn    O
syrup    O
,    O
sugar    O
,    O
water    O
,    O
glutinous    O
rice    O
flour    O
,    O
wafer    O
paper    O
(    O
potato    O
starch    O
,    O
sweet    O
potato    O
starch    O
,    O
rapeseed    O
oil    O
,    O
soy    O
lecithin    O
)    O
,    O
natural    O
flavor    O
,    O
FD&C    B-Naphthalene114958564
Red    I-Naphthalene114958564
No.    I-Naphthalene114958564
40    I-Naphthalene114958564
.    O

These    O
concerns    O
have    O
led    O
the    O
U.S.    O
FDA    O
and    O
other    O
food    O
safety    O
authorities    O
to    O
regularly    O
review    O
the    O
scientific    O
literature    O
,    O
and    O
led    O
the    O
UK    O
FSA    O
to    O
commission    O
a    O
study    O
by    O
researchers    O
at    O
Southampton    O
University    O
of    O
the    O
effect    O
of    O
a    O
mixture    O
of    O
six    O
food    O
dyes    O
(    O
Tartrazine    O
,    O
Allura    B-Naphthalene114958564
Red    I-Naphthalene114958564
,    O
Ponceau    B-Naphthalene114958564
4R    I-Naphthalene114958564
,    O
Quinoline    O
Yellow    O
WS    O
,    O
Sunset    O
Yellow    O
FCF    O
and    O
Carmoisine    O
(    O
dubbed    O
the    O
"    O
Southampton    O
6    O
"    O
)    O
)    O
and    O
sodium    O
benzoate    O
(    O
a    O
preservative    O
)    O
on    O
children    O
in    O
the    O
general    O
population    O
,    O
who    O
consumed    O
them    O
in    O
beverages    O
;    O
the    O
study    O
published    O
in    O
2007    O
.    O

Scheme    O
1    O
shows    O
the    O
synthesis    O
of    O
the    O
oxetane    O
D    O
ring    O
from    O
the    O
C    O
ring    O
starting    O
from    O
the    O
(    O
+    O
)    O
enantiomer    O
of    O
the    O
Wieland-Miescher    B-Naphthalene114958564
ketone    I-Naphthalene114958564
(    O
1    O
)    O
.    O

Asymmetric    O
synthesis    O
of    O
the    O
Wieland-Miescher    B-Naphthalene114958564
ketone    I-Naphthalene114958564
is    O
also    O
based    O
on    O
proline    O
.    O

JWH-019    B-Naphthalene114958564

JWH-019    B-Naphthalene114958564

JWH-176    B-Naphthalene114958564
is    O
an    O
analgesic    O
drug    O
which    O
acts    O
as    O
a    O
cannabinoid    O
receptor    O
agonist    O
.    O

Nafoxadol    B-Naphthalene114958564
(    O
INN    O
)    O
is    O
an    O
analgesic    O
drug    O
which    O
was    O
never    O
marketed    O
.    O

Tideglusib    B-Naphthalene114958564

Nadoxolol    B-Naphthalene114958564

vedaprofen    B-Naphthalene114958564
(    O
INN    O
)    O

Panuramine    B-Naphthalene114958564
(    O
Wy-26,002    B-Naphthalene114958564
)    O
is    O
an    O
antidepressant    O
which    O
was    O
synthesized    O
in    O
1981    O
by    O
Wyeth    O
.    O

2β-Propanoyl-3β-(2-naphthyl)-tropane    B-Naphthalene114958564
(    O
WF-23    O
)    O

PEN    O
is    O
a    O
polyester    O
polymer    O
of    O
naphthalene-2,6-dicarboxylic    B-Naphthalene114958564
acid    I-Naphthalene114958564
and    O
ethylene    O
glycol    O
.    O

Naphthalenetetracarboxylic    B-Naphthalene114958564
dianhydride    I-Naphthalene114958564
is    O
an    O
organic    O
compound    O
related    O
to    O
naphthalene    O
.    O

givinostat    B-Naphthalene114958564
(    O
INN    O
)    O

Naphthylvinylpyridine    B-Naphthalene114958564
(    O
NVP    O
)    O
is    O
a    O
naphthalene    O
derivative    O
that    O
possesses    O
anticholinergic    O
activity    O
similar    O
to    O
that    O
of    O
atropine    O
.    O

For    O
example    O
,    O
two    O
useful    O
pigments    O
of    O
the    O
perinone    B-Naphthalene114958564
class    O
are    O
generated    O
by    O
condensation    O
with    O
phenylenediamine    O
.    O

JWH-018    B-Naphthalene114958564

MDMB    O
-    O
CHMICA    O
acts    O
as    O
a    O
highly    O
potent    O
full    O
agonist    O
of    O
the    O
CB1    O
receptor    O
with    O
an    O
efficacy    O
of    O
94%    O
and    O
an    O
EC50    O
value    O
of    O
0.14    O
nM    O
,    O
which    O
is    O
approximately    O
8    O
times    O
lower    O
than    O
the    O
EC50    O
of    O
JWH-018    B-Naphthalene114958564
(    O
1.13    O
nM    O
)    O
and    O
twofold    O
lower    O
than    O
AB    O
-    O
CHMINACA    O
(    O
0.27    O
nM    O
)    O
.    O

JWH-018    B-Naphthalene114958564

JWH-018    B-Naphthalene114958564

JWH-018    B-Naphthalene114958564

It    O
is    O
the    O
indole    O
2-ethyl    O
derivative    O
of    O
related    O
compound    O
JWH-018    B-Naphthalene114958564
.    O

JWH-018    B-Naphthalene114958564

JWH-018    B-Naphthalene114958564

JWH-018    B-Naphthalene114958564

(    O
ca)any    O
compound    O
(    O
not    O
being    O
clonitazene    O
,    O
etonitazene    O
,    O
acemetacin    O
,    O
atorvastatin    O
,    O
bazedoxifene    O
,    O
indometacin    O
,    O
losartan    O
,    O
olmesartan    O
,    O
proglumetacin    O
,    O
telmisartan    O
,    O
viminol    O
,    O
zafirlukast    O
or    O
a    O
compound    O
for    O
the    O
time    O
being    O
specified    O
in    O
sub    O
-    O
paragraph    O
(    O
c    O
)    O
above    O
)    O
structurally    O
related    O
to    O
1-pentyl-3-(1-naphthoyl)indole    O
(    O
JWH-018    B-Naphthalene114958564
)    O
,    O
in    O
that    O
the    O
four    O
sub    O
-    O
structures    O
,    O
that    O
is    O
to    O
say    O
the    O
indole    O
ring    O
,    O
the    O
pentyl    O
substituent    O
,    O
the    O
methanone    O
linking    O
group    O
and    O
the    O
naphthyl    O
ring    O
,    O
are    O
linked    O
together    O
in    O
a    O
similar    O
manner    O
,    O
whether    O
or    O
not    O
any    O
of    O
the    O
sub    O
-    O
structures    O
have    O
been    O
modified    O
,    O
and    O
whether    O
or    O
not    O
substituted    O
in    O
any    O
of    O
the    O
linked    O
sub    O
-    O
structures    O
with    O
one    O
or    O
more    O
univalent    O
substituents    O
and    O
,    O
where    O
any    O
of    O
the    O
sub    O
-    O
structures    O
have    O
been    O
modified    O
,    O
the    O
modifications    O
of    O
the    O
sub    O
-    O
structures    O
are    O
limited    O
to    O
any    O
of    O
the    O
following    O
,    O
that    O
is    O
to    O
say—    O

17α-Hydroxylase/17,20-lyase    O
(    O
CYP17A1    O
)    O
inhibitors    O
such    O
as    O
abiraterone    O
acetate    O
,    O
etomidate    O
,    O
galeterone    O
,    O
ketoconazole    O
,    O
and    O
orteronel    B-Naphthalene114958564
inhibit    O
the    O
production    O
of    O
androgens    O
and    O
glucocorticoids    O
and    O
are    O
used    O
to    O
reduce    O
androgen    O
levels    O
in    O
the    O
treatment    O
of    O
prostate    O
cancer    O
.    O

Polyethylene    B-Naphthalene114958564
naphthalate    I-Naphthalene114958564
has    O
been    O
found    O
to    O
exhibit    O
scintillation    O
by    O
itself    O
without    O
any    O
additives    O
and    O
is    O
expected    O
to    O
replace    O
existing    O
plastic    O
scintillators    O
due    O
to    O
higher    O
performance    O
and    O
lower    O
price    O
.    O

Polyethylene    B-Naphthalene114958564
naphthalate    I-Naphthalene114958564
(    O
poly(ethylene    B-Naphthalene114958564
2,6-naphthalate    I-Naphthalene114958564
or    O
PEN    B-Naphthalene114958564
)    O
is    O
a    O
polyester    O
with    O
good    O
barrier    O
properties    O
(    O
even    O
better    O
than    O
Polyethylene    O
terephthalate    O
)    O
.    O

The    O
compounds    O
listed    O
for    O
control    O
were    O
ethylphenidate    O
,    O
propylphenidate    O
,    O
isopropylphenidate    O
,    O
methylnaphthidate    B-Naphthalene114958564
and    O
3,4-Dichloromethylphenidate    O
.    O

It    O
is    O
even    O
more    O
closely    O
related    O
to    O
HDMP-28    B-Naphthalene114958564
,    O
which    O
acts    O
as    O
a    O
potent    O
serotonin    O
–    O
norepinephrine–    O

HDMP-28    B-Naphthalene114958564

:    O
N07XX03    O
Xaliproden    B-Naphthalene114958564

BP-897    B-Naphthalene114958564

1-Methylnaphthalene    B-Naphthalene114958564

Naphthylamphetamine    B-Naphthalene114958564

Naphthylisopropylamine    B-Naphthalene114958564

1,8-Bis(dimethylamino)naphthalene    B-Naphthalene114958564
is    O
an    O
organic    O
compound    O
with    O
the    O
formula    O
C10H6(NMe2)2    O
(    O
Me    O
=    O
methyl    O
)    O
.    O

It    O
is    O
often    O
referred    O
by    O
the    O
trade    O
name    O
Proton    B-Naphthalene114958564
Sponge    I-Naphthalene114958564
,    O
a    O
trademark    O
of    O
Sigma    O
-    O
Aldrich    O
.    O

"N","O"-Dimethyl-4-(2-naphthyl)piperidine-3-carboxylate    B-Naphthalene114958564

Ponceau    B-Naphthalene114958564
4R    I-Naphthalene114958564
,    O
used    O
in    O
the    O
UK    O
formulation    O
,    O
is    O
prohibited    O
by    O
the    O
FDA    O
.    O

These    O
concerns    O
have    O
led    O
the    O
U.S.    O
FDA    O
and    O
other    O
food    O
safety    O
authorities    O
to    O
regularly    O
review    O
the    O
scientific    O
literature    O
,    O
and    O
led    O
the    O
UK    O
FSA    O
to    O
commission    O
a    O
study    O
by    O
researchers    O
at    O
Southampton    O
University    O
of    O
the    O
effect    O
of    O
a    O
mixture    O
of    O
six    O
food    O
dyes    O
(    O
Tartrazine    O
,    O
Allura    B-Naphthalene114958564
Red    I-Naphthalene114958564
,    O
Ponceau    B-Naphthalene114958564
4R    I-Naphthalene114958564
,    O
Quinoline    O
Yellow    O
WS    O
,    O
Sunset    O
Yellow    O
FCF    O
and    O
Carmoisine    O
(    O
dubbed    O
the    O
"    O
Southampton    O
6    O
"    O
)    O
)    O
and    O
sodium    O
benzoate    O
(    O
a    O
preservative    O
)    O
on    O
children    O
in    O
the    O
general    O
population    O
,    O
who    O
consumed    O
them    O
in    O
beverages    O
;    O
the    O
study    O
published    O
in    O
2007    O
.    O

Ponceau    B-Naphthalene114958564

2-Naphthylamine    B-Naphthalene114958564
is    O
one    O
of    O
two    O
isomeric    O
aminonaphthalenes    O
,    O
compounds    O
with    O
the    O
formula    O
C10H7NH2    O
.    O

It    O
is    O
also    O
useful    O
for    O
transamination    O
reactions    O
of    O
2-aminonaphthalene    B-Naphthalene114958564
.    O

2-Naphthylamine    B-Naphthalene114958564

2,6-Dimethylnaphthalene    B-Naphthalene114958564

1,4-Naphthoquinone    B-Naphthalene114958564
,    O
of    O
which    O
the    O
Vitamin    O
K    O
group    O
compounds    O
are    O
derivatives    O

1,4-Naphthoquinone    B-Naphthalene114958564
or    O
para-naphthoquinone    B-Naphthalene114958564
is    O
an    O
organic    O
compound    O
derived    O
from    O
naphthalene    O
.    O

Naphthyl    B-Naphthalene114958564
isothiocyanate    I-Naphthalene114958564

1-Naphthaleneacetamide    B-Naphthalene114958564

PAS    O
formed    O
part    O
of    O
the    O
standard    O
treatment    O
for    O
tuberculosis    O
prior    O
to    O
the    O
introduction    O
of    O
rifampicin    B-Naphthalene114958564
and    O
pyrazinamide    O
.    O

Its    O
potency    O
is    O
less    O
than    O
that    O
of    O
the    O
current    O
five    O
first    O
-    O
line    O
drugs    O
(    O
isoniazid    O
,    O
rifampicin    B-Naphthalene114958564
,    O
ethambutol    O
,    O
pyrazinamide    O
,    O
and    O
streptomycin    O
)    O
for    O
treating    O
tuberculosis    O
and    O
its    O
cost    O
is    O
higher    O
,    O
but    O
it    O
is    O
still    O
useful    O
in    O
the    O
treatment    O
of    O
multidrug    O
-    O
resistant    O
tuberculosis    O
.    O

When    O
taken    O
with    O
rifampicin    B-Naphthalene114958564
,    O
the    O
levels    O
of    O
rifampicin    B-Naphthalene114958564
in    O
the    O
blood    O
fall    O
by    O
about    O
half    O
.    O

A    O
preliminary    O
trial    O
of    O
antibiotic    O
therapy    O
with    O
doxycycline    O
and    O
rifampin    B-Naphthalene114958564
at    O
McMaster    O
University    O
had    O
indicated    O
that    O
it    O
was    O
effective    O
in    O
delaying    O
the    O
progress    O
of    O
the    O
disease    O
:    O
"    O
In    O
conclusion    O
,    O
a    O
3-month    O
course    O
of    O
doxycycline    O
and    O
rifampin    O
reduced    O
cognitive    O
worsening    O
at    O
6    O
months    O
of    O
follow    O
-    O
up    O
in    O
patients    O
with    O
mild    O
to    O
moderate    O
AD    O
.    O
"    O

Rifampicin    B-Naphthalene114958564
.    O

Rifampin    B-Naphthalene114958564

Inducers    O
of    O
hepatic    O
microsomal    O
enzymes    O
such    O
as    O
barbiturates    O
,    O
phenytoin    O
,    O
and    O
rifampicin    B-Naphthalene114958564
can    O
reduce    O
the    O
half    O
-    O
life    O
of    O
dexamethasone    O
.    O

The    O
metabolism    O
of    O
NOMAC    O
is    O
dependent    O
on    O
CYP3A4    O
,    O
so    O
inhibitors    O
and    O
inducers    O
of    O
this    O
enzyme    O
such    O
as    O
ketoconazole    O
and    O
rifampicin    B-Naphthalene114958564
,    O
respectively    O
,    O
as    O
well    O
as    O
some    O
anticonvulsants    O
,    O
may    O
pose    O
a    O
clinically    O
significant    O
drug    O
interaction    O
with    O
NOMAC    O
.    O

These    O
horses    O
are    O
typically    O
treated    O
with    O
rifampin    B-Naphthalene114958564
in    O
addition    O
to    O
one    O
of    O
the    O
previously    O
mentioned    O
antibiotics    O
.    O

Currently    O
,    O
a    O
multidrug    O
treatment    O
(    O
MDT    O
)    O
is    O
recommended    O
by    O
the    O
World    O
Health    O
Organization    O
,    O
including    O
dapsone    O
,    O
rifampicin    B-Naphthalene114958564
and    O
clofazimine    O
.    O

The    O
search    O
for    O
additional    O
anti    O
-    O
leprosy    O
drugs    O
led    O
to    O
the    O
use    O
of    O
clofazimine    O
and    O
rifampicin    B-Naphthalene114958564
in    O
the    O
1960s    O
and    O
1970s    O
.    O

The    O
search    O
for    O
more    O
effective    O
anti    O
-    O
leprosy    O
drugs    O
led    O
to    O
the    O
use    O
of    O
clofazimine    O
and    O
rifampicin    B-Naphthalene114958564
in    O
the    O
1960s    O
and    O
1970s    O
.    O

A    O
dermatologist    O
or    O
general    O
physician    O
usually    O
administers    O
combination    O
therapy    O
of    O
drugs    O
used    O
for    O
tuberculosis    O
,    O
such    O
as    O
Rifampicin    B-Naphthalene114958564
,    O
Isoniazid    O
and    O
Pyrazinamide    O
(    O
possibly    O
with    O
either    O
streptomycin    O
or    O
ethambutol    O
)    O
.    O

Ulipristal    O
acetate    O
is    O
likely    O
to    O
interact    O
with    O
substrates    O
of    O
CYP3A4    O
,    O
like    O
rifampicin    B-Naphthalene114958564
,    O
phenytoin    O
,    O
St    O
John    O
's    O
wort    O
,    O
carbamazepine    O
or    O
ritonavir    O
,    O
therefore    O
concomitant    O
use    O
with    O
these    O
agents    O
is    O
not    O
recommended    O
.    O

rifampin    B-Naphthalene114958564

Rifampin    B-Naphthalene114958564
prophylactically    O

Rifampin    B-Naphthalene114958564

Dapsone    O
and    O
rifampin    B-Naphthalene114958564

Rifampicin    B-Naphthalene114958564

Rifampicin    B-Naphthalene114958564

Rifampin    B-Naphthalene114958564

Chloramphenicol    O
,    O
vancomycin    O
,    O
streptomycin    O
were    O
all    O
found    O
to    O
completely    O
inhibit    O
growth    O
,    O
though    O
it    O
was    O
resistant    O
to    O
rifampin    B-Naphthalene114958564
.    O

Today    O
,    O
the    O
drugs    O
of    O
choice    O
for    O
treating    O
leprosy    O
are    O
dapsone    O
,    O
rifampicin    B-Naphthalene114958564
and    O
clofazimine    O
.    O

In    O
cases    O
where    O
antibiotics    O
have    O
been    O
suggested    O
to    O
affect    O
the    O
efficiency    O
of    O
birth    O
control    O
pills    O
,    O
such    O
as    O
for    O
the    O
broad    O
-    O
spectrum    O
antibiotic    O
rifampicin    B-Naphthalene114958564
,    O
these    O
cases    O
may    O
be    O
due    O
to    O
an    O
increase    O
in    O
the    O
activities    O
of    O
hepatic    O
liver    O
enzymes    O
'    O
causing    O
increased    O
breakdown    O
of    O
the    O
pill    O
's    O
active    O
ingredients    O
.    O

Since    O
then    O
,    O
drugs    O
such    O
as    O
isoniazid    O
and    O
rifampin    B-Naphthalene114958564
have    O
been    O
used    O
.    O

Resistance    O
of    O
"    O
Mycobacterium    O
tuberculosis    O
"    O
to    O
isoniazid    O
,    O
rifampin    B-Naphthalene114958564
,    O
and    O
other    O
common    O
treatments    O
has    O
become    O
an    O
increasingly    O
relevant    O
clinical    O
challenge    O
.    O

In    O
contrast    O
to    O
bacterial    O
RNA    O
polymerases    O
,    O
T7    O
polymerase    O
is    O
not    O
inhibited    O
by    O
the    O
antibiotic    O
rifampicin    B-Naphthalene114958564
.    O

For    O
people    O
with    O
MRSA    O
bacteremia    O
in    O
the    O
setting    O
of    O
vancomycin    O
failure    O
the    O
IDSA    O
recommends    O
high    O
-    O
dose    O
daptomycin    O
,    O
if    O
the    O
isolate    O
is    O
susceptible    O
,    O
in    O
combination    O
with    O
another    O
agent    O
(    O
e.g.    O
gentamicin    O
,    O
rifampin    B-Naphthalene114958564
,    O
linezolid    O
,    O
TMP    O
-    O
SMX    O
,    O
or    O
a    O
beta    O
-    O
lactam    O
antibiotic    O
)    O
.    O

Rifampin    B-Naphthalene114958564

CYP2A6    O
is    O
known    O
to    O
be    O
inducible    O
by    O
phenobarbital    O
and    O
rifampicin    B-Naphthalene114958564
,    O
and    O
it    O
is    O
suspected    O
that    O
other    O
antiepileptic    O
drugs    O
may    O
also    O
have    O
this    O
effect    O
.    O

rifampicin    B-Naphthalene114958564
(    O
antibacterial    O
)    O

It    O
is    O
also    O
produced    O
as    O
a    O
side    O
-    O
product    O
in    O
the    O
labelling    O
of    O
amino    O
acids    O
with    O
dansyl    B-Naphthalene114958564
chloride    I-Naphthalene114958564
.    O

JWH-073    B-Naphthalene114958564

JWH-073    B-Naphthalene114958564

JWH-073    B-Naphthalene114958564

Condensation    O
with    O
acenaphthoquinone    B-Naphthalene114958564
gives    O
8    O
,    O
a    O
dye    O
of    O
the    O
so    O
-    O
called    O
Ciba    O
-    O
Scarlet    O
type    O
,    O
while    O
condensation    O
of    O
7    O
with    O
isatin    O
results    O
in    O
the    O
thio    O
-    O
Indigo    O
dye    O
9    O
.    O

Globoidnan    B-Naphthalene114958564
A    I-Naphthalene114958564
is    O
a    O
lignan    O
found    O
in    O
"    O
Eucalyptus    O
globoidea    O
"    O
,    O
a    O
tree    O
native    O
to    O
Australia    O
.    O

Oxazine    O
derivatives    O
:    O
Nile    B-Naphthalene114958564
red    I-Naphthalene114958564
,    O
Nile    B-Naphthalene114958564
blue    I-Naphthalene114958564
,    O
cresyl    O
violet    O
,    O
oxazine    O
170    O
,    O
etc    O
.    O

Naftifine    B-Naphthalene114958564
,    O
an    O
allylamine    O
antifungal    O
drug    O
for    O
the    O
topical    O
treatment    O
of    O
tinea    O
pedis    O
,    O
tinea    O
cruris    O
,    O
and    O
tinea    O
corporis    O

naftifine    B-Naphthalene114958564

It    O
was    O
known    O
for    O
six    O
major    O
products    O
,    O
including    O
[    O
[    O
Lovaza|Omacor    O
/    O
Lovaza](Omega-3    O
)    O
]    O
,    O
Axid(H2    O
blocker    O
)    O
,    O
Dynacirc    O
CR    O
(    O
calcium    O
channel    O
blocker    O
)    O
,    O
Antara    O
(    O
fenofibrate    O
)    O
,    O
InnoPran    B-Naphthalene114958564
XL    I-Naphthalene114958564
(    O
beta    O
blocker    O
)    O
,    O
Lescol    O
XL    O
(    O
Fluvastatin    O
)    O
)    O
and    O
Rythmol    O
SR    O
(    O
Class    O
IC    O
anti    O
-    O
arrhythmic    O
)    O
.    O

James    O
W.    O
Black    O
synthesises    O
propranolol    B-Naphthalene114958564
,    O
the    O
first    O
beta    O
blocker    O
(    O
used    O
for    O
regulation    O
of    O
angina    O
pectoris    O
)    O
,    O
which    O
becomes    O
the    O
world    O
's    O
best    O
-    O
selling    O
drug    O
.    O

Propranolol    B-Naphthalene114958564

Propranolol    B-Naphthalene114958564

Propranolol    B-Naphthalene114958564

Medications    O
that    O
have    O
been    O
reported    O
to    O
provide    O
some    O
relief    O
are    O
isoniazid    O
,    O
carbamazepine    O
,    O
propranolol    B-Naphthalene114958564

The    O
effects    O
of    O
beta    O
-    O
agonists    O
such    O
as    O
dobutamine    O
can    O
be    O
reversed    O
by    O
administering    O
beta    O
-    O
blockers    O
such    O
as    O
propranolol    B-Naphthalene114958564
.    O

Propranolol    B-Naphthalene114958564

Agents    O
which    O
have    O
been    O
used    O
clinically    O
to    O
stimulate    O
and    O
assess    O
GH    O
secretion    O
are    O
arginine    O
,    O
levodopa    O
,    O
clonidine    O
,    O
epinephrine    O
and    O
propranolol    B-Naphthalene114958564
,    O
glucagon    O
and    O
insulin    O
.    O

Taking    O
ketamine    O
along    O
with    O
propranolol    B-Naphthalene114958564
and    O
doxazosin    O
may    O
cause    O
hypotension    O
,    O
and    O
combining    O
ketamine    O
with    O
lisdexamfetamine    O
and    O
amphetamine    O
/    O
dextroamphetamine    O
will    O
lead    O
to    O
cardiovascular    O
problems    O
.    O

The    O
sport    O
also    O
faced    O
its    O
first    O
major    O
doping    O
case    O
,    O
when    O
Kim    O
Jong    O
-    O
su    O
of    O
North    O
Korea    O
was    O
stripped    O
of    O
his    O
medals    O
in    O
50    O
metre    O
pistol    O
and    O
10    O
metre    O
air    O
pistol    O
after    O
testing    O
positive    O
for    O
propranolol    B-Naphthalene114958564
,    O
a    O
beta    O
blocker    O
that    O
some    O
performers    O
use    O
to    O
reduce    O
stage    O
fright    O
and    O
some    O
surgeons    O
use    O
to    O
reduce    O
hand    O
tremors    O
during    O
operations    O
.    O

Kim    O
Jong    O
-    O
su    O
of    O
North    O
Korea    O
originally    O
won    O
the    O
silver    O
medal    O
in    O
the    O
50    O
metre    O
pistol    O
and    O
bronze    O
in    O
the    O
10    O
metre    O
air    O
pistol    O
,    O
but    O
was    O
disqualified    O
after    O
he    O
tested    O
positive    O
for    O
propranolol    B-Naphthalene114958564
.    O

In    O
this    O
manner    O
they    O
indeed    O
generated    O
a    O
positive    O
feedback    O
:    O
the    O
beta    O
blocker    O
propranolol    B-Naphthalene114958564
reduced    O
the    O
release    O
.    O

Cimetidine    O
,    O
omeprazole    O
,    O
oxcarbazepine    O
,    O
ticlopidine    O
,    O
topiramate    O
,    O
ketoconazole    O
,    O
itraconazole    O
,    O
disulfiram    O
,    O
fluvoxamine    O
,    O
isoniazid    O
,    O
erythromycin    O
,    O
probenecid    O
,    O
propranolol    B-Naphthalene114958564
,    O
imipramine    O
,    O
ciprofloxacin    O
,    O
fluoxetine    O
,    O
and    O
valproic    O
acid    O
prolong    O
the    O
action    O
of    O
diazepam    O
by    O
inhibiting    O
its    O
elimination    O
.    O

Propranolol    B-Naphthalene114958564
was    O
not    O
found    O
to    O
increase    O
the    O
discontinuation    O
success    O
rate    O
.    O

In    O
the    O
1940s    O
and    O
50s    O
,    O
the    O
company    O
established    O
its    O
pharmaceutical    O
business    O
and    O
developed    O
a    O
number    O
of    O
key    O
products    O
,    O
including    O
Paludrine    O
(    O
1940s    O
,    O
an    O
anti    O
-    O
malarial    O
drug    O
)    O
,    O
halothane    O
(    O
1951    O
,    O
an    O
anaesthetic    O
agent    O
)    O
,    O
Inderal    B-Naphthalene114958564
(    O
1965    O
,    O
a    O
beta    O
-    O
blocker    O
)    O
,    O
tamoxifen    O
(    O
1978    O
,    O
a    O
frequently    O
used    O
drug    O
for    O
breast    O
cancer    O
)    O
,    O

:*    O
Propral    O
(    O
"    O
propranolol    B-Naphthalene114958564
"    O
)    O

Many    O
of    O
these    O
uses    O
have    O
been    O
exemplified    O
in    O
the    O
syntheses    O
of    O
various    O
pharmaceuticals    O
including    O
the    O
β-blocker    O
("S")-propranolol    B-Naphthalene114958564
,    O
the    O
HIV    O
protease    O
inhibitor    O
Amprenavir    O
(    O
Vertex    O
478    O
)    O
,    O
and    O
construction    O
of    O
the    O
carbohydrate    O
subunit    O
of    O
the    O
anthracycline    O
class    O
of    O
antibiotics    O
,    O
L    O
-    O
Acosamine    O
.    O

The    O
effects    O
of    O
excess    O
thyroid    O
hormone    O
typically    O
respond    O
to    O
the    O
administration    O
of    O
a    O
non    O
-    O
selective    O
beta    O
blocker    O
,    O
such    O
as    O
propranolol    B-Naphthalene114958564
(    O
as    O
most    O
of    O
the    O
symptoms    O
are    O
driven    O
by    O
increased    O
levels    O
of    O
adrenaline    O
and    O
its    O
effect    O
on    O
the    O
β-adrenergic    O
receptors    O
)    O
.    O

Zileuton    O
is    O
a    O
weak    O
inhibitor    O
of    O
CYP1A2    O
and    O
thus    O
has    O
three    O
clinically    O
important    O
drug    O
interactions    O
,    O
which    O
include    O
increasing    O
theophylline    O
,    O
and    O
propranolol    B-Naphthalene114958564
levels    O
.    O

The    O
drug    O
has    O
been    O
shown    O
to    O
increase    O
the    O
serum    O
concentration    O
or    O
effects    O
of    O
theophylline    O
,    O
propranolol    B-Naphthalene114958564
,    O
and    O
warfarin    O
,    O
although    O
significant    O
increase    O
in    O
prothrombin    O
time    O
is    O
not    O
obvious    O
.    O

Two    O
of    O
the    O
most    O
valuable    O
drug    O
treatments    O
for    O
essential    O
tremor    O
are    O
propranolol    B-Naphthalene114958564
,    O
a    O
beta    O
blocker    O
,    O
and    O
primidone    O
,    O
an    O
anticonvulsant    O
.    O

Class    O
II    O
—    O
Beta    O
blockers    O
(    O
carvedilol    O
,    O
propranolol    B-Naphthalene114958564
,    O
esmolol    O
,    O
timolol    O
,    O
metoprolol    O
,    O
atenolol    O
,    O
bisoprolol    O
)    O

Treatment(s    O
)    O
with    O
mixed    O
success    O
:    O
omalizumab    O
(    O
anti    O
-    O
IgE    O
therapy    O
)    O
,    O
danazol    O
(    O
synthetic    O
androgen    O
)    O
,    O
propranolol    B-Naphthalene114958564
(    O
beta    O
blocker    O
)    O
,    O
zileuton    O
(    O
antileukotriene    O
)    O
.    O

North    O
Korean    O
shooter    O
Kim    O
Jong    O
Su    O
was    O
tested    O
positive    O
for    O
the    O
banned    O
substance    O
propranolol    B-Naphthalene114958564
,    O
and    O
thereby    O
stripped    O
off    O
his    O
two    O
medals    O
from    O
the    O
pistol    O
events    O
.    O

1-Naphthol    O
is    O
a    O
metabolite    O
of    O
the    O
insecticide    O
carbaryl    B-Naphthalene114958564
and    O
naphthalene    O
.    O

1-Naphthol    O
is    O
a    O
precursor    O
to    O
a    O
variety    O
of    O
insecticides    O
including    O
carbaryl    B-Naphthalene114958564
and    O
pharmaceuticals    O
including    O
nadolol    O
.    O

Interactions    O
between    O
pesticides    O
and    O
chytridiomycosis    O
were    O
examined    O
in    O
2007    O
,    O
and    O
sublethal    O
exposure    O
to    O
the    O
pesticide    O
carbaryl    B-Naphthalene114958564
(    O
a    O
cholinesterase    O
inhibitor    O
)    O
was    O
shown    O
to    O
increase    O
susceptibility    O
of    O
foothill    O
yellow    O
-    O
legged    O
frogs    O
(    O
"    O
Rana    O
boylii    O
"    O
)    O
to    O
chytridiomycosis    O
.    O

Control    O
is    O
usually    O
attempted    O
with    O
carbaryl    B-Naphthalene114958564
insecticide    O
in    O
the    O
form    O
of    O
powder    O
,    O
liquid    O
,    O
and    O
bait    O
.    O

The    O
most    O
common    O
chemical    O
control    O
method    O
used    O
is    O
carbaryl    B-Naphthalene114958564
(    O
typically    O
sold    O
as    O
"    O
Sevin    O
Dust    O
"    O
)    O
bait    O
.    O

Infected    O
banana    O
plants    O
can    O
be    O
sprayed    O
with    O
an    O
insecticide    O
like    O
Sevin    B-Naphthalene114958564
to    O
reduce    O
or    O
get    O
rid    O
of    O
the    O
aphid    O
population    O
,    O
since    O
control    O
of    O
viruses    O
starts    O
with    O
control    O
of    O
the    O
vectors    O
.    O

Infections    O
of    O
the    O
eyelashes    O
may    O
be    O
treated    O
with    O
either    O
petroleum    O
jelly    O
applied    O
twice    O
daily    O
for    O
10    O
days    O
or    O
malathion    O
,    O
phenothrin    O
,    O
and    O
carbaryl    B-Naphthalene114958564
.    O

Nafimidone    B-Naphthalene114958564
is    O
an    O
anticonvulsant    O
drug    O
of    O
the    O
imidazole    O
class    O
.    O

NNC    B-Naphthalene114958564
63-0532    I-Naphthalene114958564

Frequently    O
used    O
topical    O
retinoids    O
include    O
adapalene    B-Naphthalene114958564
,    O
isotretinoin    O
,    O
retinol    O
,    O
tazarotene    O
,    O
and    O
tretinoin    O
.    O

Differin    B-Naphthalene114958564
,    O
a    O
topical    O
retinoid    O
for    O
acne    O
.    O

Nerolin    B-Naphthalene114958564
(    O
orange    O
flowers    O
)    O

4-NEMD    B-Naphthalene114958564

Besides    O
millions    O
of    O
gallons    O
of    O
road    O
tar    O
,    O
products    O
included    O
phenol    O
,    O
the    O
cresols    O
and    O
xylenols    O
,    O
naphthalene    O
,    O
pyridine    O
bases    O
,    O
creosote    O
,    O
benzene    O
,    O
toluene    O
,    O
xylene    O
,    O
solvent    O
naphtha    O
,    O
ammonium    O
sulphate    O
and    O
ammonia    O
solution    O
,    O
sulphuric    O
acid    O
,    O
picolines    O
,    O
quinoline    O
,    O
quinaldine    O
,    O
acenaphthene    B-Naphthalene114958564
,    O
anthracene    O
and    O
dicyclopentadiene    O
.    O

reaction    O
of    O
acenaphthene    B-Naphthalene114958564
plus    O
succinic    O
acid    O
Organic    O
Syntheses    O
,    O
Coll    O
.    O

Indocyanine    B-Naphthalene114958564
green    I-Naphthalene114958564
angiography    O
can    O
be    O
used    O
to    O
assess    O
the    O
health    O
of    O
the    O
retina    O
in    O
the    O
affected    O
area    O
which    O
can    O
be    O
useful    O
in    O
making    O
a    O
treatment    O
decision    O
.    O

Cyanine    O
derivatives    O
:    O
cyanine    O
,    O
indocarbocyanine    B-Naphthalene114958564
,    O
oxacarbocyanine    O
,    O
thiacarbocyanine    O
,    O
and    O
merocyanine    O

"N"-Phenylnaphthalen-1-amine    B-Naphthalene114958564

1-Chloronaphthalene    B-Naphthalene114958564

Ansofaxine    O
,    O
PRC200-SS    B-Naphthalene114958564
,    O
WY-46824    O
and    O
S33005    O
for    O
related    O
analogs    O
.    O

During    O
development    O
it    O
was    O
known    O
as    O
FE200486    B-Naphthalene114958564
.    O

1,2,3,4-Tetraphenylnaphthalene    B-Naphthalene114958564
is    O
a    O
polycyclic    O
aromatic    O
hydrocarbon    O
commonly    O
prepared    O
in    O
the    O
undergraduate    O
teaching    O
laboratory    O
as    O
an    O
introduction    O
to    O
the    O
Diels    O
-    O
Alder    O
reaction    O
,    O
in    O
this    O
case    O
between    O
benzyne    O
,    O
which    O
acts    O
as    O
the    O
dienophile    O
,    O
(    O
generated    O
"    O
in    O
situ    O
"    O
)    O
and    O
tetraphenylcyclopentadienone    O
,    O
which    O
acts    O
as    O
the    O
diene    O
.    O

butenafine    B-Naphthalene114958564

Dibunate    B-Naphthalene114958564
is    O
a    O
cough    O
suppressant    O
.    O

Two    O
important    O
components    O
of    O
its    O
essential    O
oil    O
are    O
patchoulol    O
and    O
norpatchoulenol    B-Naphthalene114958564
.    O

These    O
reactions    O
afford    O
dihydronaphthalene    B-Naphthalene114958564
:    O

Other    O
less    O
expensive    O
synthetic    O
auxin    O
analogs    O
on    O
the    O
market    O
for    O
use    O
in    O
horticulture    O
are    O
indole-3-butyric    O
acid    O
(    O
IBA    O
)    O
and    O
1-naphthaleneacetic    B-Naphthalene114958564
acid    I-Naphthalene114958564
(    O
NAA    O
)    O
.    O

In    O
a    O
study    O
of    O
Camellia    O
sinensis    O
the    O
effect    O
of    O
three    O
different    O
auxins    O
,    O
IBA    O
,    O
IAA    O
and    O
NAA    B-Naphthalene114958564
were    O
examined    O
to    O
determine    O
the    O
relative    O
effect    O
of    O
each    O
auxin    O
on    O
root    O
formation    O
.    O

dapoxetine    B-Naphthalene114958564
(    O
INN    O
)    O

David    O
T.    O
Wong    O
-    O
discovered    O
drug    O
Fluoxetine    O
and    O
atomoxetine    O
,    O
duloxetine    O
and    O
dapoxetine    B-Naphthalene114958564

1-Naphthylamine    B-Naphthalene114958564
is    O
an    O
aromatic    O
amine    O
derived    O
from    O
naphthalene    O
.    O

1-Naphthylamine    B-Naphthalene114958564

These    O
include    O
;    O
JWH-018    B-Naphthalene114958564
,    O
JWH-022    O
,    O
JWH-073    B-Naphthalene114958564
,    O
JWH-081    O
,    O
JWH-122    B-Naphthalene114958564
,    O
JWH-201    O
,    O
JWH-203    O
,    O
JWH-210    O
,    O
JWH-250    O
,    O
JWH-302    O
,    O
AM-694    O
,    O
AM-2201    B-Naphthalene114958564
,    O
RCS-4    O
,    O
RCS-4    O
butyl    O
homologue    O
,    O
2-methoxy    O
isomer    O
of    O
RCS-4    O
,    O
and    O
2-methoxy    O
isomer    O
of    O
RCS-4    O
butyl    O
homologue    O
,    O
which    O
were    O
banned    O
on    O
16    O
August    O
2011    O
,    O
JWH-019    B-Naphthalene114958564
,    O
JWH-200    O
and    O
AM-1220    O
,    O
which    O
were    O
banned    O
on    O
14    O
October    O
2011    O
,    O
AM-2233    O
,    O
banned    O
on    O
29    O
December    O
2011    O
,    O
AM-1248    O
,    O
AM-2232    O
and    O
UR-144    O
,    O
banned    O
on    O
6    O
April    O
2012    O
,    O
and    O
the    O
stimulant    O
methylhexanamine    O
,    O
banned    O
on    O
9    O
April    O
2012    O
.    O

AM-2201    B-Naphthalene114958564

THJ-2201    O
—    O
the    O
indazole    O
analogue    O
of    O
AM-2201    B-Naphthalene114958564
.    O

AM-2201    B-Naphthalene114958564

RS-127,445    B-Naphthalene114958564


